Autolus Therapeutics PLC 8-K filings

Autolus Therapeutics plc announced robust second-quarter 2026 financial results, driven by significant AUCATZYL sales growth, leading to an increase in full-year revenue guidance and a strengthened financial position.

Autolus Therapeutics plc announced a significant increase in its 2026 revenue guidance for AUCATZYL and secured a substantial credit facility, extending its cash runway into Q2 2028.

Autolus Therapeutics plc has entered into a $250 million senior secured notes facility with Perceptive Credit Holdings V, LP, alongside the issuance of warrants, to fund its operations and development.

Autolus Therapeutics plc has published its UK Annual Report and Accounts for the year ended December 31, 2025, and has issued a notice for its upcoming Annual General Meeting.

Autolus Therapeutics plc announced first quarter 2026 financial results, reporting a significant increase in AUCATZYL net product revenue to $26.2 million and achieving positive gross margin for its acute lymphoblastic leukemia business.

Autolus Therapeutics plc is implementing a workforce reduction of approximately 13% to improve operational efficiency and reduce operating expenses, while reiterating its 2026 revenue guidance.

Autolus Therapeutics has dismissed Ernst & Young LLP (UK) and appointed Ernst & Young LLP (US) as its new independent auditor.

Autolus Therapeutics plc hosted an investor event detailing its Acute Lymphoblastic Leukemia (ALL) business, focusing on its product candidates AUCATZYL (obecabtagene autoleucel) and obe-cel, highlighting real-world data, clinical trial progress, and future strategies.

Autolus Therapeutics announced its Q4 and full-year 2025 financial results, reporting strong AUCATZYL revenue and projecting positive gross margin in 2026, alongside significant clinical pipeline advancements.

Autolus Therapeutics' subsidiary signed a 10-year Master Service Agreement with AGC Biologics for critical lentiviral vector supply, ensuring CAR-T product manufacturing.

Autolus Therapeutics announced preliminary unaudited net product revenue for AUCATZYL in 2025, provided 2026 revenue guidance, and updated on pipeline advancements, projecting cash runway into Q4 2027.

Autolus Therapeutics plc announced the appointment of Ryan Richardson, a seasoned healthcare and investment banking executive with extensive experience from BioNTech, to its Board of Directors.

Autolus Therapeutics reports Q3 2025 financial results with $21.1M AUCATZYL revenue, significant clinical progress, and strategic leadership appointments.

Autolus Therapeutics announced Q2 2025 net product revenue of $20.9 million for AUCATZYL, alongside key regulatory approvals in the UK and EU, and progress in its autoimmune disease pipeline.

Autolus Therapeutics plc announced that all nine resolutions, including the adoption of 2024 accounts, director re-elections, and a new employee share plan, were duly passed by shareholders at its 2025 Annual General Meeting held on June 26, 2025.

Autolus Therapeutics plc has scheduled its 2025 Annual General Meeting for June 26, 2025, where shareholders will vote on the 2024 Annual Report, director re-elections, remuneration policies, and a new Employee Share Purchase Plan allocating 3 million shares.

Autolus Therapeutics plc announced that Drs. Joseph Anderson and Martin Murphy will not seek re-election to the Board of Directors at the upcoming 2025 Annual General Meeting, with their decision not stemming from any disagreement with management or the Board.

Autolus Therapeutics announces Q1 2025 financial results, including $9.0 million in AUCATZYL net product revenue, and highlights regulatory approval in the UK and progress in autoimmune disease trials.

Autolus Therapeutics plc will provide a corporate update at an R&D investor event on April 23, 2025, with a live webcast and archived replay available on the company's website.

Autolus Therapeutics reports the resignation of its VP of Finance, Andrew Mercieca, and the appointment of CFO Rob Dolski as the principal accounting officer.

Autolus Therapeutics announces its Q4 and full year 2024 financial results, highlighting the successful U.S. commercial launch of AUCATZYL and plans for future growth in autoimmune diseases.

Autolus Therapeutics is gearing up for commercial execution and market expansion, driven by the FDA-approved AUCATZYL and the promising obe-cel product franchise.

Autolus Therapeutics reported its third quarter 2024 financial results, highlighted by the FDA approval of its CAR T-cell therapy, AUCATZYL, and provided updates on its clinical programs.

Autolus Therapeutics has secured FDA approval for AUCATZYL, a CAR T-cell therapy for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, marking a significant advancement in treatment options.

Autolus Therapeutics presented a corporate update at the KBC Life Sciences Conference, emphasizing the progress of its lead candidate, obe-cel, and its broader pipeline.

Autolus Therapeutics has appointed Matthias Will, M.D., as Chief Development Officer, effective September 30, 2024, to lead the company's development organization.

Autolus Therapeutics has amended its lease agreement to secure £18.5 million in funding for improvements to its Nucleus manufacturing facility.

Autolus Therapeutics announced its Q2 2024 financial results and provided updates on the progress of its lead product, obe-cel, including a PDUFA target date of November 16, 2024, for potential US commercial launch.

Autolus Therapeutics successfully passed all nine resolutions at its 2024 Annual General Meeting, including the adoption of the 2023 financial statements and the re-election of several directors.

Autolus Therapeutics has announced its 2024 Annual General Meeting date and released its UK Annual Report for the year ended December 31, 2023.